Elegen and Nutcracker Therapeutics to pilot first fully cell-free manufacturing process for RNA-based personalized cancer therapeutics

Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot program to demonstrate the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapeutics (PCTs).